T1	Participants 123 201	patients treated with concomitant, quadruple, and levofloxacin-based therapies
T2	Participants 272 306	individuals with amalgam fillings.
T3	Participants 578 707	dyspeptic patients with amalgam fillings and the effect of the amalgam fillings on H. pylori eradication rates in these patients.
T4	Participants 729 873	Four hundred and seventy-five patients who presented with dyspeptic complaints and underwent upper gastrointestinal endoscopy and gastric biopsy
